Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc. - Common Stock (NQ:LTRN)

1.725 -0.035 (-1.99%)
Streaming Delayed Price Updated: 11:07 AM EDT, Sep 11, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Lantern Pharma Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Recap: Lantern Pharma Q2 Earnings ↗
  Lantern Pharma (NASDAQ:LTRN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma's New Phase 2 Clinical Trial –Harmonic™ — Approved for Launch by the FDA ↗
When most people think of lung cancer, they often picture a smoker. 
Via Benzinga
News headline image
Earnings Scheduled For March 10, 2022 ↗
Companies Reporting Before The Bell • Despegar.com (NYSE:DESP) is expected to report quarterly loss at $0.08 per share on revenue of $110.93 million. • ProShares... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Lantern Pharma Gets FDA Clearance for Mid-Stage Lung Cancer Study ↗
The Food and Drug Administration (FDA) has announced clearance to Lantern Pharma (NASDAQ: LTRN) to proceed with Phase 2 clinical trial of its investigational new drug LP-300 in combination with... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer
From Lantern Pharma Inc.
Via Business Wire
News headline image
Lantern Pharma Management to Speak at Multiple Investor and Scientific Conferences in May 2022
From Lantern Pharma Inc.
Via Business Wire
News headline image
Recap: Lantern Pharma Q1 Earnings ↗
Lantern Pharma (NASDAQ:LTRN) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Lantern Pharma missed estimated... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Lantern Pharma Earnings Preview ↗
Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Tuesday, 2022-05-03. Here's what investors need to know before the announcement. Analysts estimate that Lantern... 
Via Benzinga
News headline image
Lantern Pharma Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
ORLANDO, FL / ACCESSWIRE / April 14, 2022 / RedChip Companies, Inc. today announced that Lantern Pharma (NASDAQ:LTRN),a clinical stage biopharmaceutical company using its proprietary RADR® artificial... 
From RedChip
Via AccessWire
Topics Artificial Intelligence
News headline image
Lantern Pharma: Q4 Earnings Insights ↗
Lantern Pharma (NASDAQ:LTRN) reported its Q4 earnings results on Thursday, March 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
Earnings Outlook For Lantern Pharma ↗
Lantern Pharma (NASDAQ:LTRN) is set to give its latest quarterly earnings report on Thursday, 2022-03-10. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
Benzinga Announces This Week's All Access Guests ↗
Benzinga is thrilled to announce the guest lineup for our next All Access show, presented by RedChip, set to air Friday, January 28 at 9:15 am ET. The Lineup 9:15 am:... 
Via Benzinga
News headline image
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg ↗
Biotech stocks reversed course in the week ending March 4, as the Ukrainian crisis weighed down on the broader market as well as the sector. The iShares Biotechnology ETF (... 
Via Benzinga
News headline image
RedChip Partners with Benzinga to Host Exclusive Small-Cap CEO Interview Series on January 28
ORLANDO, FL / ACCESSWIRE / January 26, 2022 / RedChip Companies, Inc., an international investor relations, media, and research firm focused on microcap and small-cap companies, is pleased to announce... 
From RedChip
Via AccessWire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers SAB Biotherapeutics (NASDAQ:SABS) stock moved upwards by 15.0% to $6.3 during Monday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
News headline image
Lantern Pharma's LP-184 Receives Rare Pediatric, Orphan Drug Tags For Rare Form Of Cancer ↗
The FDA has granted Rare Pediatric Disease and Orphan Drug Designations to Lantern Pharma Inc's (NASDAQ: LTRN) LP-184 for Atypical Teratoid Rhabdoid Tumor... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers ChemoCentryx (NASDAQ:CCXI) stock increased by 70.43% to $33.41 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 74.6... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Nanobiotix (NASDAQ:NBTX) shares rose 13.2% to $12.0 during Thursday's regular session. The market value of their outstanding shares is at $417.9 million.... 
Via Benzinga
News headline image
Earnings Scheduled For November 1, 2021 ↗
Companies Reporting Before The Bell • ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third quarter. • Kiniksa Pharmaceuticals (NASDAQ:... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 7, 2021 ↗
Upgrades For State Street Corporation (NYSE: 
Via Benzinga
News headline image
Lantern Pharma to Present at Microcap Rodeo's Fall Harvest - Best Ideas from the Buy-Side on Wednesday, October 6, 2021
DALLAS, TX / ACCESSWIRE / September 30, 2021 / Lantern Pharma (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to... 
From Lantern Pharma
Via AccessWire
Topics Artificial Intelligence
News headline image
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 5) Bicycle Therapeutics plc (... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 4) Avadel Pharmaceuticals plc (... 
Via Benzinga
News headline image
36 of the Best Ideas Companies to Present at the Fall Harvest - Best Ideas from the Buy-Side Virtual Investor Conference on October 5th - 8th, 2021
RALEIGH, NC / ACCESSWIRE / October 4, 2021 / The Fall Harvest - Best Ideas from the Buy-Side will take place on October 5th - 8th, 2021, where 36 SmallCap, MicroCap and NanoCap public companies will be... 
From MicroCap Rodeo
Via AccessWire
News headline image
The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.